Recently, Cancer Research Institute CEO and Director of Scientific Affairs Jill O’Donnell-Tormey, Ph.D., appeared in two informative Facebook Live broadcasts to discuss current developments and challenges in cancer immunotherapy.
Last week, during the Second International Cancer Immunotherapy Conference (CICON16), O’Donnell-Tormey moderated a Q&A panel with renowned cancer immunology experts Elizabeth Jaffee, M.D., of Johns Hopkins Medicine and Philip Greenberg, M.D., of Fred Hutchinson Cancer Research Center.
Earlier this week, O’Donnell-Tormey sat down with Business Insider’s pharmaceutical and biotech reporter Lydia Ramsey to share the latest advancements in cancer immunotherapy, and highlight CRI’s role in pioneering and leading this vital new field of cancer treatment.
We are grateful for the continued opportunities to provide updates on cancer immunotherapy’s progress and promising future.
CICON16: The Future of Cancer Immunotherapy
Read Previous Article
Checkpoint Inhibitors Benefit Lung Cancer Patients in Clinical Trials
Read Next Article
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
We spoke with Dr. Yvonne Chen to learn more about her work in chemical engineering to fight cancer and what she hopes to accomplish during the next five years as a CRI Lloyd J. Old STAR.
We round up the latest immunotherapy for pancreatic cancer news and research from the scientists, physicians, and patients changing the future of pancreatic cancer treatment.